0720 GMT - Roche was dealt a setback by a U.S. Food and Drug Administration advisory committee, which voted against approval of the Swiss pharmaceutical company's Columvi lymphoma drug, Vontobel's Stefan Schneider says in a research note. The FDA's Oncologic Drugs Advisory Committee on Tuesday voted 8 to 1 against Columvi's approval as a second-line lymphoma treatment--for patients who aren't eligible for standard treatment--, arguing it needed more data as patients in a late-stage trial weren't representative of the U.S. patient population. The committee issues nonbinding recommendations, but the FDA--due to decide on Columvi by July--generally follows them, Vontobel says. The prospect of Roche getting approval for Columvi as a third-line treatment could be at risk as well, the analyst says. Shares fall 0.3%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 21, 2025 03:20 ET (07:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。